Clinical/Translational Cancer Immunotherapy

Loss of ADAR1 in macrophages in combination with interferon gamma suppresses tumor growth by remodeling the tumor microenvironment
Weiwei Lin, Yikai Luo, Jie Wu, Haowan Zhang, Ge Jin, Chahua Guo, Hang Zhou, Han Liang, Xiaoyan Xu

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (11) e007402; DOI: 10.1136/jitc-2023-007402
Th17-inducing dendritic cell vaccines stimulate effective CD4 T cell-dependent antitumor immunity in ovarian cancer that overcomes resistance to immune checkpoint blockade
Yan Luo, Barath Shreeder, James W Jenkins, Huashan Shi, Purushottam Lamichhane, Kexun Zhou, Deborah A Bahr, Sophia Kurian, Katherine A Jones, Joshua I Daum, Navnita Dutta, Brian M Necela, Martin J Cannon, Matthew S Block, Keith L Knutson

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (11) e007661; DOI: 10.1136/jitc-2023-007661
PER2 binding to HSP90 enhances immune response against oral squamous cell carcinoma by inhibiting IKK/NF-κB pathway and PD-L1 expression
Zhiwei Zhang, Deping Sun, Hong Tang, Jie Ren, Shilin Yin, Kai Yang

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (11) e007627; DOI: 10.1136/jitc-2023-007627
First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors
Rom Leidner, Kevin Conlon, Douglas G McNeel, Andrea Wang-Gillam, Sumati Gupta, Robert Wesolowski, Monica Chaudhari, Nadia Hassounah, Jong Bong Lee, Lang Ho Lee, Jessica A O’Keeffe, Nancy Lewis, George N Pavlakis, John A Thompson

Journal for ImmunoTherapy of Cancer Oct 2023, 11 (10) e007725; DOI: 10.1136/jitc-2023-007725
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma
Krisztian Homicsko, Panagiota Zygoura, Maxim Norkin, Stephanie Tissot, Nicholas Shakarishvili, Sanjay Popat, Alessandra Curioni-Fontecedro, Mary O'Brien, Anthony Pope, Riyaz Shah, Patricia Fisher, James Spicer, Amy Roy, David Gilligan, Sylvie Rusakiewicz, Ekaterina Fortis, Nesa Marti, Roswitha Kammler, Stephen P Finn, Georges Coukos, Urania Dafni, Solange Peters, Rolf A Stahel

Journal for ImmunoTherapy of Cancer Oct 2023, 11 (10) e007585; DOI: 10.1136/jitc-2023-007585
Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D
Junsik Park, Jung Bok Lee, Myong Cheol Lim, Byoung-Gie Kim, Jae-Weon Kim, Sunghoon Kim, Chel Hun Choi, Hee Seung Kim, Sang Yoon Park, Jung-Yun Lee

Journal for ImmunoTherapy of Cancer Oct 2023, 11 (10) e007444; DOI: 10.1136/jitc-2023-007444
Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies
Nurudeen A Adegoke, Tuba N Gide, Yizhe Mao, Camelia Quek, Ellis Patrick, Matteo S Carlino, Serigne N Lo, Alexander Maxwell Menzies, Ines Pires da Silva, Ismael A Vergara, Georgina Long, Richard A Scolyer, James S Wilmott

Journal for ImmunoTherapy of Cancer Oct 2023, 11 (10) e007144; DOI: 10.1136/jitc-2023-007144
Divergent tumor and immune cell reprogramming underlying immunotherapy response and immune-related adverse events in lung squamous cell carcinoma
Minjiang Chen, Pengfei Ma, Yongchang Zhang, Dong Wang, Zhuang Yu, Yujie Fu, Xiaojing Zhao, Mengzhao Wang, Guanglei Zhuang, Ying Jing

Journal for ImmunoTherapy of Cancer Oct 2023, 11 (10) e007305; DOI: 10.1136/jitc-2023-007305
AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors
Sophia Frentzas, Steven Kao, Rang Gao, Hao Zheng, Ahsan Rizwan, Nageshwar Budha, Luz de la Hoz Pedroza, Wei Tan, Tarek Meniawy

Journal for ImmunoTherapy of Cancer Oct 2023, 11 (10) e005829; DOI: 10.1136/jitc-2022-005829
Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer
Abdul Rafeh Naqash, Justin D McCallen, Emma Mi, Sanna Iivanainen, Mona A Marie, Daria Gramenitskaya, James Clark, Jussi Pekka Koivunen, Shravanti Macherla, Sweta Jonnalagadda, Shanker Polsani, Rahim Ali Jiwani, Maida Hafiz, Mahvish Muzaffar, Leonardo Brunetti, Chipman R G Stroud, Paul R Walker, Kun Wang, Youngmin Chung, Eytan Ruppin, Se-Hoon Lee, Li V Yang, David J Pinato, Joo Sang Lee, Alessio Cortellini

Journal for ImmunoTherapy of Cancer Oct 2023, 11 (10) e007310; DOI: 10.1136/jitc-2023-007310

Main menu

Clinical/Translational Cancer Immunotherapy

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Clinical/Translational Cancer Immunotherapy

Pages